Evidence map›Paper›PMID 41420316›Full record

ArticleHeadache2026

First successful protocol for desensitization to eptinezumab.

Benoit Gerard, Hubert Praudel, Michel Lanteri-Minet, Elise Van Obberghen, Fanny Rocher-Moreau, Johanna Rousset, Ulysse Jacquier, Sylvie Leroy, Margot Delin

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Headache, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Benoit GerardDépartement de pneumologie et d'oncologie thoracique, Centre Hospitalier Universitaire de Nice, IHU RespirERA, Université Côte d'Azur, Nice, France.
Hubert PraudelDépartement de pneumologie et d'oncologie thoracique, Centre Hospitalier Universitaire de Nice, IHU RespirERA, Université Côte d'Azur, Nice, France.
Michel Lanteri-MinetPain Department, Centre Hospitalier Universitaire de Nice, FHU Inovpain, URC2A, Université Côte d'Azur, Nice, France.
Elise Van ObberghenPain Department, Centre Hospitalier Universitaire de Nice, FHU Inovpain, URC2A, Université Côte d'Azur, Nice, France.
Fanny Rocher-MoreauCentre régional de pharmacovigilance, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
Johanna RoussetCentre régional de pharmacovigilance, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
Ulysse JacquierDépartement de pneumologie et d'oncologie thoracique, Centre Hospitalier Universitaire de Nice, IHU RespirERA, Université Côte d'Azur, Nice, France.
Sylvie LeroyDépartement de pneumologie et d'oncologie thoracique, Centre Hospitalier Universitaire de Nice, IHU RespirERA, Université Côte d'Azur, Nice, France.
Margot DelinDépartement de pneumologie et d'oncologie thoracique, Centre Hospitalier Universitaire de Nice, IHU RespirERA, Université Côte d'Azur, Nice, France.ORCID 0009-0008-2262-2501

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEptinezumab is an anti-calcitonin gene-related peptide monoclonal antibody used for migraine prevention. During clinical trials, hypersensitivity to eptinezumab was described without a clear underlying mechanism. To determine if the reaction was immunoglobulin E-mediated, the team of Nice University Hospital (Nice, France) performed the eptinzeumab skin tests. A 10-step desensitization protocol has been proposed to manage these reactions.

findingsTwo patients presenting with immediate hypersensitivity reactions underwent the eptinezumab skin test. Neither skin test was positive, suggesting a non-immunoglobulin E-mediated mechanism. The patients then completed the desensitization protocol successfully.

conclusionThis hospital-based 10-step desensitization protocol appears safe and effective.

Indexed as

Antibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsDesensitization, ImmunologicDrug HypersensitivityMigraine DisordersAdultFemaleHumansMaleMiddle AgedSkin TestsAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor Antagonistseptinezumaballergydesensitizationeptinezumabskin test

Identifiers

PMID41420316
PMCPMC12916455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.